Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
xCures
Adela, Inc
Var2 Pharmaceuticals
Day One Biopharmaceuticals, Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
Tempus AI
Quadriga Biosciences, Inc.
Xennials Therapeutics Australia Pty Ltd
Gilead Sciences
SpeciCare
Celgene
Tocagen Inc.
INSYS Therapeutics Inc
Pharmacyclics LLC.